Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.